Cencora (NYSE:COR) Hits New 12-Month High - Here's Why

Cencora, Inc. (NYSE:COR - Get Free Report)'s share price hit a new 52-week high on Monday . The company traded as high as $262.56 and last traded at $261.65, with a volume of 1502754 shares. The stock had previously closed at $254.58.

Analysts Set New Price Targets

Several research firms have recently issued reports on COR. JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. StockNews.com downgraded shares of Cencora from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Evercore ISI raised their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company upped their price target on shares of Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research report on Wednesday, January 29th. Finally, Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Cencora presently has an average rating of "Moderate Buy" and a consensus price target of $277.90.

Remove Ads

Cencora Stock Performance

The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company has a market cap of $50.74 billion, a price-to-earnings ratio of 37.22, a PEG ratio of 1.31 and a beta of 0.51. The stock has a 50 day simple moving average of $244.34 and a 200 day simple moving average of $238.39.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,648 shares of company stock valued at $2,862,342. Insiders own 10.80% of the company's stock.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently made changes to their positions in the company. Hickory Asset Management Inc. bought a new stake in Cencora during the fourth quarter valued at $572,000. Sylvest Advisors LLC acquired a new position in shares of Cencora in the 4th quarter valued at about $1,105,000. Insight Wealth Strategies LLC grew its position in shares of Cencora by 124.6% during the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock valued at $4,549,000 after buying an additional 11,232 shares during the last quarter. Cerity Partners LLC lifted its holdings in Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock worth $8,881,000 after acquiring an additional 3,610 shares during the last quarter. Finally, Vontobel Holding Ltd. boosted its stake in Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after acquiring an additional 1,995 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.